The Exchange had sought clarification from Onesource Specialty Pharma Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Limited Review Report/ Independent Auditor's Report is not in the format prescribed by SEBI The response of the Company is enclosed.
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
OneSource Specialty Pharma (formerly Stelis Biopharma) reported a major turnaround for Q4 and FY ended March 31, 2025. Q4 FY25 revenue from operations surged to Rs 4,774.14 million (up from Rs 731.43 million in Q4 FY24), with profit after tax of Rs 1,748.77 million versus a loss of Rs 400.12 million a year ago. For full FY25, the company swung to a profit of Rs 193.10 million from a loss of Rs 3,904.02 million in FY24. Basic EPS for FY25 was Rs 1.75 compared to a loss of Rs 93.97 per share. Auditor Deloitte Haskins & Sells issued an unmodified opinion. The Board also approved consolidation of Singapore operations (Stelis Pte Ltd and Strides Softgel Pte Ltd) into Onesource Specialty Pte Ltd, appointed M/s. D V & Associates as Secretarial Auditor for 5 years, and confirmed full redemption of 20,000 Non-Convertible Debentures on November 28, 2024. Total equity grew sharply to Rs 59,201.01 million from Rs 3,977.43 million, largely reflecting business combinations.
The strong swing to profitability is positive for shareholders, though much of the growth is driven by inorganic expansion (large goodwill of Rs 19,761.42 million). The SEBI query about the auditor's report format appears to be a minor procedural compliance issue and is unlikely to materially affect the stock.